Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
about
Supramolecular Complexation of Carbohydrates for the Bioavailability Enhancement of Poorly Soluble DrugsPhase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyPhase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based reviewTyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.Novel camptothecin derivatives as topoisomerase I inhibitors.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.Polymer-drug conjugates for novel molecular targets.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Recent advances in oral anticancer agents for colon cancer.Polymer-drug conjugates: recent progress on administration routes.Advances in oral delivery of anti-cancer prodrugs.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization.An overview of quinoline as a privileged scaffold in cancer drug discovery.Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.
P2860
Q26777831-6E0FB5E1-207F-4B07-A75B-87A9ECA559F2Q33382930-B6B3878B-B62A-41FF-BAD6-A53CD4B64C30Q33387707-86F1BE0F-3E58-4649-AA34-21A0956ABBE4Q35008045-37A5A385-473F-412C-8074-FF3EF0D1CA36Q35597039-22B67CB8-0040-490B-A374-40AE59E20E42Q36551126-03D85C23-F299-42E4-9B49-5261977F664EQ37173199-4F1BC1D4-1CEB-4F6C-B39C-5DD04BA26DC8Q37345974-13050368-E160-4C3C-9788-783FE165682AQ37369825-C5B5221F-C68D-435A-A1DF-3424976767B0Q37481337-591F6FBA-9CD6-46DA-B50B-2F1DBACF33B3Q37575709-778DD825-0387-474D-B279-FAB9FDE0147AQ37782076-9B850CD3-A56A-45E5-8C17-ECFB26F5AB81Q37834445-02A3CBD3-EA65-4DD8-9435-76B18A236929Q38167885-7C16C768-A128-4634-86C1-2152B1F8E8EFQ38206549-66B95DBF-4124-4240-9D08-BCA5C5AD192AQ38862820-3C410F2F-93D5-4B45-82E6-9B795AB6E51DQ38933314-35DA1278-D707-4086-B850-1C9044D26B1FQ39223151-353E337F-9FE6-4BE0-AD7C-6646901101CCQ39235281-C93FC06D-E83F-4D6E-AD84-1D7F7097287BQ44076450-75A8945B-9F41-40A6-8B71-CC117F06AD5AQ52901455-84388E8F-0FB2-402F-A424-2A8013874C83Q54958449-A9957FE6-88E6-4B26-B471-6556D40BEA0F
P2860
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@ast
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@en
type
label
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@ast
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@en
prefLabel
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@ast
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@en
P2093
P1476
Phase I pharmacokinetic, food ...... in patients with solid tumors.
@en
P2093
Allan T van Oosterom
Ferry A L M Eskens
Floris A de Jong
Ger-Jan Sanderink
Herlinde Dumez
Jaap Verweij
Johan Selleslach
José Thomas
Judith Ter Steeg
Maja J A de Jonge
P304
P356
10.1158/1078-0432.CCR-04-1758
P407
P577
2005-02-01T00:00:00Z